Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ensartinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Approval of Ensartinib for ALK-Positive NSCLC
    FDA Approval of Ensartinib for ALK-Positive NSCLC

    19 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241218355621/en

    BUSINESSWIRE
    19 Dec 2024
    Share Share
    FDA Has Accepted the New Drug Application (NDA) for Ensartinib
    FDA Has Accepted the New Drug Application (NDA) for Ensartinib

    13 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240313675039/en

    BUSINESSWIRE
    13 Mar 2024
    Share Share
    Ensartinib Secured Its First Approval for 1st Line Treatment in ALK+ NSCLC
    Ensartinib Secured Its First Approval for 1st Line Treatment in ALK+ NSCLC

    22 Mar 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220322006197/en

    BUSINESSWIRE
    22 Mar 2022
    Share Share
    Takeda offers value-based pricing for Alunbrig
    Takeda offers value-based pricing for Alunbrig

    09 Nov 2021

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/marketing/takeda-value-based-drug-pricing-lung-cancer-alunbrig-pfizer-xalkori-discount-rebate

    Angus Liu FIERCEPHARMA
    09 Nov 2021
    Share Share
    Vanderbilt Oncologists Publish Results of First Study
    Vanderbilt Oncologists Publish Results of First Study

    29 Oct 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20191029005146/en/Vanderbilt-Oncologists-Publish-Results-Study-Demonstrate-Clinical

    BUSINESSWIRE
    29 Oct 2019
    Share Share
    The Lancet Respiratory Medicine Published Study Shows Ensartinib
    The Lancet Respiratory Medicine Published Study Shows Ensartinib

    18 Oct 2019

    // BIOSPACE

    https://www.biospace.com/article/releases/the-lancet-respiratory-medicine-published-study-shows-ensartinib-holds-promise-as-a-new-treatment-option-for-alk-positive-non-small-cell-lung-cancer-nsclc-/?s=95

    BIOSPACE
    18 Oct 2019
    Share Share